Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.74% | 37.10% | 42.88% | 54.58% | 56.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 267.01% | -- | 61.02% | 58.30% | -65.52% |
| Total Other Non-Cash Items | -69.52% | 198.58% | -61.77% | -75.22% | 417.48% |
| Change in Net Operating Assets | 10.12% | -369.83% | -806.35% | -138.58% | -117.28% |
| Cash from Operations | 30.40% | 30.42% | 41.51% | 41.40% | 39.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -78.69% | -78.69% | -78.69% |
| Total Debt Repaid | 40.92% | 65.19% | 63.28% | 34.12% | 27.55% |
| Issuance of Common Stock | -54.66% | -70.82% | -83.83% | 30.34% | 139.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,581.87% | 781.75% | 527.33% | 639.38% | 18.20% |
| Cash from Financing | 12.85% | 21.60% | -58.40% | 13.94% | -0.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 217.51% | 188.50% | -3,039.14% | 128.31% | 77.80% |